Flinn is a technology company.
Flinn has raised $9.0M across 2 funding rounds.
Flinn has raised $9.0M in total across 2 funding rounds.
Flinn.ai is an AI-driven SaaS platform designed to automate regulatory and quality compliance processes for MedTech companies, addressing the complexities of regulations like EU MDR and IVDR.[1][2][3] It serves MedTech manufacturers—from SMEs to enterprises managing portfolios of 5-100 technical files and low- to high-risk medical devices—by monitoring 40+ million life science publications, 20+ million incident reports, millions of complaints, and hundreds of global standards, enabling 1-click audit readiness, real-time monitoring, automated de-duplication, and market insights.[1][3] Trusted by over 100 MedTech companies across 14 countries with offices in Vienna, Berlin, and Paris, Flinn.ai boosts efficiency tenfold, reduces costs, and accelerates product launches to improve global access to critical devices like baby defibrillators.[1][2][3] The company recently raised €10 million in funding within 18 months, fueling its growth amid rising regulatory pressures.[2]
Flinn.ai emerged in Vienna to tackle the escalating compliance burdens in MedTech, particularly from EU MDR implementation, which has driven up costs and forced companies to abandon niche products.[2] Founded by a team blending expertise from medtech manufacturers, regulated industries, top consultancies, fast-scaling startups, and global tech giants, the company adopted an experimentation-driven, customer-centric product development approach.[1][2] Early traction came from clients like Erbe Elektromedizin GmbH, where its safety database monitoring software automated repetitive tasks, cut personnel costs, and boosted employee satisfaction by shifting focus to value-adding work.[2] This validated its mission to enhance medical enterprises' ability to introduce and run products effectively, ultimately improving health outcomes worldwide.[2]
Flinn.ai rides the wave of AI-driven regulatory tech (RegTech) in MedTech, where exploding data volumes and stringent rules like MDR/IVDR create barriers to innovation and market entry.[2][3] Its timing is ideal amid post-MDR challenges, where compliance costs have led to product discontinuations and reduced device availability, amplifying the need for automation to sustain niche innovations.[2] Market forces favoring Flinn.ai include AI's maturation for handling regulated data and growing investor interest, evidenced by its €10M raise, positioning it to empower 100+ global MedTech leaders.[1][2] By accelerating compliance, it influences the ecosystem positively, enabling faster launches of life-saving devices and fostering a more innovative, accessible MedTech sector.[1][2]
Flinn.ai is poised for rapid scaling, leveraging its €10M funding to expand AI capabilities, enter new markets beyond its 14-country footprint, and support IVDR expansions amid ongoing regulatory evolution.[2][3] Trends like AI integration in life sciences and global harmonization of standards will propel its growth, potentially capturing a larger share of the burdened MedTech compliance market.[1][2] Its influence may evolve from a compliance accelerator to a full innovation enabler, helping enterprises prioritize R&D over bureaucracy—ultimately tying back to its core impact: making critical medical devices available faster to millions worldwide.[1][2]
Flinn has raised $9.0M in total across 2 funding rounds.
Flinn's investors include 7percent Ventures, Acton Capital Partners, btov Partners, Cherry Ventures, Christian Miele, MMC Ventures, Passion Capital, Speedinvest, Akhil Paul, Charlie Songhurst, Julius Göllner, Matthias Hilpert.
Flinn has raised $9.0M across 2 funding rounds. Most recently, it raised $7.0M Seed in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $7.0M Seed | 7percent Ventures, Acton Capital Partners, btov Partners, Cherry Ventures, Christian Miele, MMC Ventures, Passion Capital, Speedinvest, Akhil Paul, Charlie Songhurst, Julius Göllner, Matthias Hilpert | |
| Dec 1, 2022 | $2.0M Seed | Cherry Ventures, LocalGlobe, MMC Ventures, Octopus Ventures, Speedinvest, Simon Lambert |